Abbott Launches the First Infant Formula in Canada with an Ingredient Identical in Structure to Immune Component Found in Breast Milk

  • 2'-Fucosyllactose Oligosaccharide (2'-FL ) is now available in Abbott's infant formula, Similac Pro-Advance®
  • HMOs, like 2'-FL, in breast milk help support a baby's immune system [1]
  • HMOs, like 2'-FL, feed good bacteria in the breastfed baby's digestive tract that are important to helping build immunity [2],[3],[4]

- Abbott (NYSE: ABT) launched its most innovative infant formula yet, Similac Pro-Advance® with 2'-Fucosyllactose Oligosaccharide † (2'-FL † ), which is the first product in Canada with this breakthrough ingredient in infant formula.

Breast milk is considered the gold standard to feed an infant, and breastfed babies tend to have stronger immune systems compared to those who are fed formula. This is due in part to the many immune components found in breastmilk, including the protective qualities of human milk oligosaccharides (HMOs). 1,5,6,7 HMOs are the third most abundant solid component of breast milk after fat and carbohydrates (lactose 1,8 ), and research has shown they play a fundamental role in a baby's digestive health and immunity. 1,3,9 One of the best-known functions of HMOs is that they act as prebiotics, nourishing the good bacteria in the baby's gut. 1,10 2'-fucosyllactose (2'-FL) (pronounced 2 fyou-ko-sil-lac-tose) is the most abundant HMO found in the breast milk of most mothers. 11,12

For some parents, breast milk is not always available or chosen. And, for babies who are not exclusively breastfed, infant formula is the only suitable and safe alternative. That's why Abbott developed a new Similac formula with 2'-FL , which is an ingredient identical in structure to 2'-FL HMO, an immune component found in breast milk. 2,3,4 Abbott is a leader in HMO and 2'-FL research, and has sponsored at least 20 clinical and pre-clinical studies on the topic, leading the company to develop Similac Pro-Advance ® with 2'-FL .

New understanding and scientific developments have allowed Abbott's scientists to harness the power of 2'-FL in infant formula , an innovation designed to help support a baby's developing immune system. New data continues to deepen the evidence for the beneficial impact of 2'-FL on infant gut and immune development.

"Parents want to know that their child is getting the nutrition they need, and breastfeeding is known to have many health benefits," says Nishta Saxena , a Registered Dietician and Nutritionist of her own practice, Vibrant Nutrition. "Parents who use formula can feel more confident, knowing that the inclusion of 2'-FL in infant formula was inspired by an immune component found in human milk."

Rachael Buck , Ph.D., Research Fellow at Abbott said, "At Abbott, we know that breast milk provides protective components a baby needs to thrive. That's why we have spent more than 20 years researching HMOs and their impact on immune and gut health so that we can understand the role they play in supporting the development of a baby's immune system during the critical first years of their life. We wanted to replicate 2'-FL found in breast milk so that more babies could possibly benefit."

Research published in the Journal of Nutrition studied more than 200 babies to compare the differences between breastfed babies and those fed formula with or without 2'-FL . 2 , 4 The peer-reviewed study found that formula-fed babies had five gaps in immune markers compared to the breastfed group. When babies were fed formula with 2'-FL , these measures of immune function were more like those seen in the breastfed reference group. 2 This shows that 2'-FL may help support baby's developing immune system.

Similac Pro-Advance® with 2'-FL will be available in all major retailers.

For further information about Similac® and the benefits of 2'-FL please visit www.similac.ca

Important notice: Breast milk is best for babies, as it contains many immune factors not available in infant formula and its use is recommended for as long as possible during infancy.

Breastfeeding provides many benefits to both mother and baby. We recommend that you speak to your healthcare professional for advice on how to feed your baby.

Not derived from human milk; identical structure to 2'-FL found in breast milk.

About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

References

1 Jantscher-Krenn E., Bode L. Human milk oligosaccharides and their potential benefits for the breast-fed neonate. Minerva Pediatr . 2012;64:83–99.
2 Goehring K et al. Similar to Those Who Are Breastfed, Infants Fed a Formula Containing 2′-Fucosyllactose Have Lower Inflammatory Cytokines in a Randomized Controlled Trial. Journal of Nutrition . 2016; 147(9)
3 Bode L. Human milk oligosaccharides: everyone needs a sugar mama. Glycobiology . 2012;22(9)
4 Marriage B. et al. Infants Fed a Lower Calorie Formula With 2′FL Show Growth and 2′FL Uptake Like Breast-Fed Infants. Journal of Pediatric Gastoenterology and Nutrition . 2015; 61(6)
5 Field CJ. The immunological components of human milk and their effect on immune development in infants. J Nutr . 2005;135(1):1–4.
6 Iyengar SR, Walker WA. Immune factors in breast milk and the development of atopic disease. J Pediatr Gastroenterol Nutr. 2012;55(6):641-7.
7 Gregory KE, Walker WA. Immunologic Factors in Human Milk and Disease Prevention in the Preterm Infant. Curr Pediatr Rep. 2013;1(4):10.
8 Zivkovic AM, German JB, Lebrilla CB, et al.  Human milk glycobiome and its impact on the infant gastrointestinal microbiota. Proc Natl Acad Sci . 2011;108(Suppl 1):4653-8.
9 Vázquez E et al. The Metabolic Fate of 2'-Fucosyllactose Depends on its Route of Administration. Abstract presented at the 50th Annual Congress of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) . 2017;N-eP-021, page 807
10 Underwood MA, Davis JCC, Kalanetra KM, et al. Digestion Of Human Milk Oligosaccharides By Bifidobacterium Breve In The Premature Infant. J Pediatr Gastroenterol Nutr. 2017;65(4):449-455.
11 Lewis ZT, Totten SM, Smilowitz JT et al. Microbiome . 2015;3:13.
12 Castanys-Munoz, E., M.J. Martin, and P.A. Prieto. 2'-fucosyllactose: an abundant, genetically determined soluble glycan present in human milk. Nutr Rev. 2013;71(12):773-89.

SOURCE Abbott

Cision View original content: https://www.newswire.ca/en/releases/archive/November2020/17/c1862.html

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×